Tenvie Therapeutics launches with $200M, acquires Denali drug candidates, led by Tony Estrada with NLRP3 and SARM1 inhibitors ...
Aspect Biosystems raises $115M Series B for bioprinted tissue therapeutics targeting diabetes and metabolic disorders, led by ...
Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, ...
Roche's Chugai partners with Araris Biotech on multi-payload ADCs, as Swiss biotech advances tech allowing multiple cytotoxic ...
Galapagos is looking for a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two ...
Vir Biotechnology reports early data on T cell engagers VIR-5818 and VIR-5500, licensed from Sanofi, showing tumor shrinkage ...
Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...
With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding
A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start ...
Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest ...
Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a ...
Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...
Aetna is going after another pharmaceutical company for alleged price fixing. The health insurance provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback